APCCC 2024: PSMA Radioligand Therapy – State of the Art
APCCC 2024, PSMA Radioligand Therapy, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PSMA-617, PSMA-1&T, PSMA-1007 rhPSMA-7, 68Ga PSMA-11, VISION trial, TheraP trial, PSMAfore trial, PSMAddition trial, 177Lu-PSMA-617, LuPSMA, SPLASH (NCT04647526) trial,177Lu-PNT2002, LuTectomy trial, ENZA-p (ANZUP 1901), JNJ-69086420, Actinium-225-labeled antibody, human Kallikrein 2, NCT04644770, 68Ga-RM2, somatostatin receptor-2 (SSTR2) PET, SSTR2 PET.